Published in J Virol on May 01, 2003
Productive replication of Vif-chimeric HIV-1 in feline cells. J Virol (2010) 0.99
TRIM5α and Species Tropism of HIV/SIV. Front Microbiol (2012) 0.96
The antiretroviral potency of APOBEC1 deaminase from small animal species. Nucleic Acids Res (2008) 0.95
Nuclear import of the preintegration complex is blocked upon infection by human immunodeficiency virus type 1 in mouse cells. J Virol (2006) 0.93
High natural permissivity of primary rabbit cells for HIV-1, with a virion infectivity defect in macrophages as the final replication barrier. J Virol (2010) 0.84
Retroviral restriction and dependency factors in primates and carnivores. Vet Immunol Immunopathol (2011) 0.83
Productive replication and evolution of HIV-1 in ferret cells. J Virol (2011) 0.82
GANP interacts with APOBEC3G and facilitates its encapsidation into the virions to reduce HIV-1 infectivity. J Immunol (2013) 0.75
Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene (1991) 38.64
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology (1995) 14.30
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol (1999) 13.55
A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell (1998) 10.14
Two distinct enhancers with different cell specificities coexist in the regulatory region of polyoma. Cell (1984) 9.47
Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev (1997) 6.88
P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev (1997) 5.13
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A (1999) 4.46
The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev (1998) 4.38
Co-receptors for HIV-1 entry. Curr Opin Immunol (1997) 4.31
Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. J Virol (1991) 3.94
Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol (1999) 3.66
Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J (1998) 3.05
Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr Biol (1999) 2.97
Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. J Virol (2000) 2.72
HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization. Immunity (1994) 2.63
Inhibition of HIV-1 progeny virion release by cell-surface CD4 is relieved by expression of the viral Nef protein. Curr Biol (1999) 2.52
A block to human immunodeficiency virus type 1 assembly in murine cells. J Virol (2000) 2.47
A human cell factor is essential for HIV-1 Rev action. EMBO J (1990) 2.43
Human chromosome 12 is required for elevated HIV-1 expression in human-hamster hybrid cells. Science (1989) 2.03
Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T. Proc Natl Acad Sci U S A (1999) 1.87
Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proc Natl Acad Sci U S A (1997) 1.74
Mouse-human heterokaryons support efficient human immunodeficiency virus type 1 assembly. J Virol (2001) 1.55
Role of the human and murine cyclin T proteins in regulating HIV-1 tat-activation. J Mol Biol (1999) 1.55
Chemokines, cytokines and HIV: a complex network of interactions that influence HIV pathogenesis. Immunol Rev (2000) 1.50
Disturbed CD4+ T cell homeostasis and in vitro HIV-1 susceptibility in transgenic mice expressing T cell line-tropic HIV-1 receptors. J Exp Med (1998) 1.46
Susceptibility of rat-derived cells to replication by human immunodeficiency virus type 1. J Virol (2001) 1.33
Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1. J Virol (2002) 1.25
Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J Exp Med (2002) 1.23
Infection of rabbits with human immunodeficiency virus. Nature (1988) 1.19
Human immunodeficiency virus type 1 infection of human CD4-transgenic rabbits. J Gen Virol (1995) 1.03
Rabbit cells expressing human CD4 and human CCR5 are highly permissive for human immunodeficiency virus type 1 infection. J Virol (1998) 1.02
Ability of small animal cells to support the postintegration phase of human immunodeficiency virus type-1 replication. Virology (2003) 0.95
Syphilis superinfection activates expression of human immunodeficiency virus I in latently infected rabbits. Am J Pathol (1991) 0.82
Human chromosome 6- and 11-encoded factors support human immunodeficiency virus type 1 Rev function in A9 cells. J Virol (1996) 0.82
Differential level in co-down-modulation of CD4 and CXCR4 primed by HIV-1 gp120 in response to phorbol ester, PMA, among HIV-1 isolates. Microbiol Immunol (2000) 0.78
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J Virol (2005) 2.35
Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science (2014) 2.11
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis (2007) 2.10
The use of nonhuman primate models in HIV vaccine development. PLoS Med (2008) 1.73
Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120. J Virol (2003) 1.42
Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy. J Infect Dis (2007) 1.36
Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques. Virology (2006) 1.34
Coreceptor switch in R5-tropic simian/human immunodeficiency virus-infected macaques. J Virol (2007) 1.32
Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1. J Virol (2002) 1.25
Recombinant extracellular domains of tetraspanin proteins are potent inhibitors of the infection of macrophages by human immunodeficiency virus type 1. J Virol (2006) 1.15
SOCS1 is an inducible host factor during HIV-1 infection and regulates the intracellular trafficking and stability of HIV-1 Gag. Proc Natl Acad Sci U S A (2008) 1.14
HLA-A2 down-regulation on primary human macrophages infected with an M-tropic EGFP-tagged HIV-1 reporter virus. J Leukoc Biol (2005) 1.09
CD8+ T cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques. Proc Natl Acad Sci U S A (2003) 1.07
A CCR5-tropic simian-HIV molecular clone capable of inducing AIDS in rhesus macaques. J Acquir Immune Defic Syndr (2005) 1.05
A truncated form of Nef selected during pathogenic reversion of simian immunodeficiency virus SIVmac239Deltanef increases viral replication. J Virol (2003) 1.02
V3 loop-determined coreceptor preference dictates the dynamics of CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaques. J Virol (2005) 1.02
Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J Virol (2010) 1.01
Induction of potent local cellular immunity with low dose X4 SHIV(SF33A) vaginal exposure. Virology (2007) 0.99
Different mutational pathways to CXCR4 coreceptor switch of CCR5-using simian-human immunodeficiency virus. J Virol (2008) 0.98
Generation of high-affinity antibody against T cell-dependent antigen in the Ganp gene-transgenic mouse. J Immunol (2005) 0.97
R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch. J Virol (2008) 0.97
Cellulose acetate 1,2-benzenedicarboxylate protects against challenge with pathogenic X4 and R5 simian/human immunodeficiency virus. AIDS (2005) 0.96
Ability of small animal cells to support the postintegration phase of human immunodeficiency virus type-1 replication. Virology (2003) 0.95
The antiretroviral potency of APOBEC1 deaminase from small animal species. Nucleic Acids Res (2008) 0.95
Human immunodeficiency virus type 1 nucleocapsid inhibitors impede trans infection in cellular and explant models and protect nonhuman primates from infection. J Virol (2009) 0.95
HTLV-1 Tax-associated hTid-1, a human DnaJ protein, is a repressor of Ikappa B kinase beta subunit. J Biol Chem (2002) 0.95
Different tempo and anatomic location of dual-tropic and X4 virus emergence in a model of R5 simian-human immunodeficiency virus infection. J Virol (2010) 0.93
Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. J Virol (2007) 0.93
Safety and distribution of cellulose acetate 1,2-benzenedicarboxylate (CAP), a candidate anti-HIV microbicide in rhesus macaques. AIDS (2005) 0.93
Properties of the surface envelope glycoprotein associated with virulence of simian-human immunodeficiency virus SHIV(SF33A) molecular clones. J Virol (2002) 0.93
CD4 mimics targeting the mechanism of HIV entry. Bioorg Med Chem Lett (2009) 0.92
Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy. J Infect Dis (2001) 0.91
Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2. J Gen Virol (2009) 0.91
Wild type and H43Y variant of human TRIM5alpha show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro. Immunogenetics (2007) 0.91
Structural dynamics of HIV-1 envelope Gp120 outer domain with V3 loop. PLoS One (2012) 0.91
Emergence of autologous neutralization-resistant variants from preexisting human immunodeficiency virus (HIV) quasi species during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy. J Infect Dis (2002) 0.88
Expansion of quasispecies diversity but no evidence for adaptive evolution of SHIV during rapid serial transfers among seronegative macaques. Virology (2004) 0.88
Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS (2006) 0.88
Molecular mechanism of hTid-1, the human homolog of Drosophila tumor suppressor l(2)Tid, in the regulation of NF-kappaB activity and suppression of tumor growth. Mol Cell Biol (2005) 0.88
CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. Bioorg Med Chem Lett (2010) 0.87
Coreceptor use in nonhuman primate models of HIV infection. J Transl Med (2011) 0.87
Efficient repeated low-dose intravaginal infection with X4 and R5 SHIVs in rhesus macaque: implications for HIV-1 transmission in humans. Virology (2007) 0.87
Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques. PLoS One (2011) 0.86
Conformational epitope consisting of the V3 and V4 loops as a target for potent and broad neutralization of simian immunodeficiency viruses. J Virol (2013) 0.86
Pathogenic consequences of vaginal infection with CCR5-tropic simian-human immunodeficiency virus SHIVSF162P3N. J Virol (2012) 0.86
Induction of simian AIDS in infant rhesus macaques infected with CCR5- or CXCR4-utilizing simian-human immunodeficiency viruses is associated with distinct lesions of the thymus. J Virol (2004) 0.84
CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents. Bioorg Med Chem (2013) 0.84
Small molecular CD4 mimics as HIV entry inhibitors. Bioorg Med Chem (2011) 0.83
Multiple human immunodeficiency virus type 1 Nef functions contribute to efficient replication in primary human macrophages. J Gen Virol (2004) 0.82
Increased infectivity in human cells and resistance to antibody-mediated neutralization by truncation of the SIV gp41 cytoplasmic tail. Front Microbiol (2013) 0.82
Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial. Intern Med (2013) 0.81
Efficient mucosal transmissibility but limited pathogenicity of R5 SHIV SF162P3N in Chinese-origin rhesus macaques. J Acquir Immune Defic Syndr (2013) 0.81
Mucosal transmissibility, disease induction and coreceptor switching of R5 SHIVSF162P3N molecular clones in rhesus macaques. Retrovirology (2013) 0.80
Identification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques. Retrovirology (2012) 0.80
Effect of B-cell depletion on coreceptor switching in R5 simian-human immunodeficiency virus infection of rhesus macaques. J Virol (2011) 0.79
Giant cell encephalitis and microglial infection with mucosally transmitted simian-human immunodeficiency virus SHIVSF162P3N in rhesus macaques. J Neurovirol (2014) 0.77
Fast disease progression in simian HIV-infected female macaque is accompanied by a robust local inflammatory innate immune and microbial response. AIDS (2015) 0.77
A CD4 mimic as an HIV entry inhibitor: pharmacokinetics. Bioorg Med Chem (2013) 0.77
The Prevalence of High Antiretroviral Coverage and Viral Suppression in Japan: an Excellent Profile for a Downstream Human Immunodeficiency Virus Care Spectrum. Jpn J Infect Dis (2016) 0.76
Cross-Neutralization Activity of Single-Chain Variable Fragment (scFv) Derived from Anti-V3 Monoclonal Antibodies Mediated by Post-Attachment Binding. Jpn J Infect Dis (2016) 0.76
Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro. J Gen Virol (2013) 0.76
Generation of a replication-competent simian-human immunodeficiency virus, the neutralization sensitivity of which can be enhanced in the presence of a small-molecule CD4 mimic. J Gen Virol (2013) 0.76
Distinct Compartmentalization in the CNS of SHIVKU-1-Infected Chinese Rhesus Macaque Is Associated With Severe Neuropathology. J Acquir Immune Defic Syndr (2015) 0.75
Impact of the Maraviroc-Resistant Mutation M434I in the C4 Region of HIV-1 gp120 on Sensitivity to Antibody-Mediated Neutralization. Jpn J Infect Dis (2015) 0.75
Determinants of HIV-1 CD4-independent brain adaptation. J Acquir Immune Defic Syndr (2017) 0.75
The impact of highly active antiretroviral therapy by the oral route on the CD8 subset in monkeys infected chronically with SHIV 89.6P. J Virol Methods (2003) 0.75